Bolstered by the overexpression of Id proteins in a wide range of human tumors and the frequent correlation with a poor prognosis, several investigators have suggested that Id proteins play key roles in the initiation and progression of cancer. Our own work identified the Retinoblastoma tumor suppressor pathway as a network that cross talks with Id proteins during development but is subverted by Id in Myc-driven cancer. However, the post-translational machinery that regulates Id proteins in normal cells is unknown. Similarly, it remains unclear whether genetic alterations leading to deregulated Id activity exist in cancer cells. Recently, we discovered that colon cancer cells acquire a missense mutation in the Id2 gene that converts Threonine-27 into the unphosphorylatable amino acid Alanine. We also found that Threonine-27 is phosphorylated by the Dyrk1 kinases in vitro and in vivo.
Our Specific Aims will focus on the regulation and function of this phosphorylation event and the destruction signals that we recently identified in Id proteins. Thus, we will define the signaling pathways converging on Threonine-27 phosphorylation and elucidate how they regulate Id2 protein function. Through biochemical and genetic approaches we will also determine why tumor cells select for the Threonine-27 to Alanine Id2 mutant protein. To address this problem in the context of the whole organism, we will generate knock-in mice that conditionally express the tumor-specific mutation of Id2. Finally, we will take advantage of state-of-the-art mass spectrometry approaches developed in our laboratory to identify and characterize novel enzymes responsible for post-translational modifications of Id proteins. Through the proposed work, we aim to provide a better understanding of the post-translational regulatory machinery for Id proteins and unravel new layers of intervention targeting the alteration of this machinery in human cancer.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Molecular Oncogenesis Study Section (MONC)
Program Officer
Spalholz, Barbara A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Columbia University (N.Y.)
Schools of Medicine
New York
United States
Zip Code
Lee, Sang Bae; Frattini, Veronique; Bansal, Mukesh et al. (2016) An ID2-dependent mechanism for VHL inactivation in cancer. Nature 529:172-7
Iavarone, Antonio; Lasorella, Anna (2014) Myc and differentiation: going against the current. EMBO Rep 15:324-5
Frattini, Veronique; Trifonov, Vladimir; Chan, Joseph Minhow et al. (2013) The integrated landscape of driver genomic alterations in glioblastoma. Nat Genet 45:1141-9
Danussi, Carla; Akavia, Uri David; Niola, Francesco et al. (2013) RHPN2 drives mesenchymal transformation in malignant glioma by triggering RhoA activation. Cancer Res 73:5140-50
Niola, Francesco; Zhao, Xudong; Singh, Devendra et al. (2013) Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. J Clin Invest 123:405-17
Niola, Francesco; Zhao, Xudong; Singh, Devendra et al. (2012) Id proteins synchronize stemness and anchorage to the niche of neural stem cells. Nat Cell Biol 14:477-87
Singh, Devendra; Chan, Joseph Minhow; Zoppoli, Pietro et al. (2012) Transforming fusions of FGFR and TACC genes in human glioblastoma. Science 337:1231-5
Coma, Silvia; Amin, Dhara N; Shimizu, Akio et al. (2010) Id2 promotes tumor cell migration and invasion through transcriptional repression of semaphorin 3F. Cancer Res 70:3823-32
Carro, Maria Stella; Lim, Wei Keat; Alvarez, Mariano Javier et al. (2010) The transcriptional network for mesenchymal transformation of brain tumours. Nature 463:318-25